Artivion (AORT)

NYSE Health Care Health Care Equipment S&P SmallCap 600
$20.21
-5.12 (-20.21%)
Close of Nov 06, 2026 · end-of-day data
Next earnings date
Not scheduled yet
No report date announced in the next three weeks.
Consensus EPS estimate
—
Shown once a date is announced.
Last report (Nov 05)
$0.08 vs $0.11 est.
Surprise -27.3%

Earnings surprise history

reported EPS vs consensus
ReportedQuarterEPS estimateReported EPSSurprise
Nov 05, 2026Sep/2026$0.11$0.08-27.3%

Our record of AORT's reports since we began tracking; it grows each quarter.

Latest results, in brief

All AORT 8-K briefs →
Nov 5, 4:07 PM ET

Artivion Q3 revenue rises 9% to $123.8 million; net loss of $7.9 million

Mixed earnings 2.02

Artivion reported third-quarter 2026 revenue of $123.8 million, up 9% from $113.4 million a year earlier, but swung to a GAAP net loss of $7.9 million, or $0.16 per diluted share, from net income of $6.5 million, or $0.13 per diluted share, in the prior-year quarter. Adjusted EBITDA fell 8% to $22.5 million, and the company narrowed its full-year 2026 revenue and adjusted EBITDA guidance ranges.

  • Q3 2026 revenue of $123.8 million, up 9% on both GAAP and constant currency bases; On-X grew 13% in constant currency.
  • Q3 2026 GAAP net loss of $(7.9) million, or $(0.16) per diluted share, versus net income of $6.5 million, or $0.13, in Q3 2025.
  • Adjusted EBITDA declined 8% to $22.5 million from $24.6 million.
  • FY 2026 revenue guidance narrowed to $484 million to $492 million from $480 million to $496 million; adjusted EBITDA guidance narrowed to $93 million to $98 million from $92 million to $99 million.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.

Quarter endedRevenueYoYEPS (diluted)YoYNet incomeNet margin
Sep 2026$123.79M+9.2% $-0.16-223.1% -$7.93M-6.4%
Jun 2026$125.76M+11.3% $-0.28-1033.3% -$13.51M-10.7%
Mar 2026$116.34M+17.5% $0.03— $1.42M1.2%
Dec 2025$115.99M+19.2% $0.05— $2.43M2.1%
Sep 2025$113.39M+18.4% $0.13— $6.50M5.7%
Jun 2025$112.97M+15.3% $0.03— $1.34M1.2%
Mar 2025$98.98M+1.6% $-0.01-105.6% -$505.00K-0.5%
Dec 2024$97.31M+3.9% $-0.39— -$16.48M-16.9%

From Artivion's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.

Annual results

Fiscal yearRevenueGrowthEPS (diluted)GrowthNet margin
FY2025$441.33M+13.6% $0.21—2.2%
FY2024$388.54M+9.8% $-0.32—-3.4%
FY2023$354.00M+12.8% $-0.75—-8.7%
FY2022$313.79M+5.0% $-0.48—-6.1%
FY2021$298.84M+18.0% $-0.38—-5.0%

Frequently asked questions

When is Artivion's next earnings date?

Artivion has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.

What did Artivion earn last quarter?

For the quarter ended Sep 2026, Artivion reported diluted EPS of $-0.16 (-223.1% year over year) on revenue of $123.79M (+9.2%).

Where do these numbers come from?

Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.

Not investment advice. Figures can be restated by the company in later filings.